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Coevolution of beneficial microorganisms with the
mammalian intestine fundamentally shapesmamma-
lian physiology. Here, we report that the intestinal
microbe Bacteroides fragilismodifies the homeosta-
sis of host invariant natural killer T (iNKT) cells by
supplementing the host’s endogenous lipid antigen
milieu with unique inhibitory sphingolipids. The
process occurs early in life and effectively impedes
iNKT cell proliferation during neonatal development.
Consequently, total colonic iNKT cell numbers are
restricted into adulthood, and hosts are protected
against experimental iNKT cell-mediated, oxazo-
lone-induced colitis. In studies with neonatal mice
lacking access to bacterial sphingolipids, we found
that treatment with B. fragilis glycosphingolipids—
exemplified by an isolated peak (MW = 717.6) called
GSL-Bf717—reduces colonic iNKT cell numbers and
confers protection against oxazolone-induced colitis
in adulthood. Our results suggest that the distinctive
inhibitory capacity of GSL-Bf717 and similar
molecules may prove useful in the treatment of
autoimmune and allergic disorders in which iNKT
cell activation is destructive.
INTRODUCTION
As humans, we require symbiotic microbes to establish and
maintain health. Microbes equipped with beneficial properties
are preferentially granted membership in our intestinal commu-
nity. Understanding the specific molecules and immune mecha-
nisms used by microbes to elicit their beneficial phenotype is a
key step toward informed use of the microbiota to help resolve
many health issues (Ba¨ckhed et al., 2005; Chow et al., 2010;
Honda and Littman, 2012). Currently, these molecules and
mechanisms remain largely unknown. One exception to thisdearth of knowledge about the contribution of specific microbial
products to the host immune system is the body of literature
on polysaccharide A (PSA) (Mazmanian et al., 2005; Mazmanian
et al., 2008; Round et al., 2011) produced by the common intes-
tinal symbiont Bacteroides fragilis.
Symbiotic bacteria possess enigmatic phenotypes that are
unusual in environmental bacterial species and pathogens. For
example, bacterial sphingolipids are produced predominantly
by species in the phylum Bacteroidetes (Ingar and Erik, 2001;
Kato et al., 1995), many of which are associated almost exclu-
sively with mammalian hosts. The only identified function of
bacterial sphingolipids is the activation of invariant natural killer
T (iNKT) cells by glycosphingolipids produced by certain soil-
dwelling Sphingomonas species in the phylum Proteobacteria,
one of only a few known sphingolipid producers outside the Bac-
teroidetes (Kinjo et al., 2005; Mattner et al., 2005). iNKT cells
recognize nonpolymorphic major histocompatibility complex
class I-like, CD1d protein-presented lipid antigens, the best
studied of which are glycosphingolipids (Cohen et al., 2009).
With their remarkable ability to quickly release high levels of
cytokines upon activation (Kronenberg, 2005; Matsuda et al.,
2008), iNKT cells are critical players in innate and adaptive
immunity. Previously, our groups demonstrated that specific
pathogen-free (SPF) mice had lower iNKT cell numbers in the
colonic lamina propria (LP) than did germ-free (GF) mice;
accordingly, SPF mice were protected from experimental iNKT
cell-mediated, oxazolone-induced colitis, whereas GF mice
were not (Olszak et al., 2012). These results suggested that
sphingolipids produced by symbiotic bacteria might play an
important role in host colonic iNKT cell homeostasis and in the
oxazolone colitis susceptibility phenotype.
RESULTS
B. fragilis Sphingolipids Modulate Host Colonic iNKT
Cell Homeostasis and Protect the Host from a Colitis
Challenge
In the model organism B. fragilis NCTC 9343, the enzyme
encoded by gene BF2461 has a high degree of homologyCell 156, 123–133, January 16, 2014 ª2014 Elsevier Inc. 123
Figure 1. B. fragilis Sphingolipids Modulate Homeostasis of Colonic LP iNKT Cells
(A) Representative fluorescence-activated cell sorting (FACS) plots of iNKT cell gating.
(B andC) The total numbers of colonic LP iNKT cells (B) and their percentages in CD3+ populations (C) were higher in GF andBFDSPT than in SPF andBFWTmice.
(D–F) B. fragilis monocolonized mice had iNKT cell counts similar to those of GF mice in lung (D), liver (E), and small intestine (F).
Data in (B) and (C) (days 21, 42, and 63) were confirmed to have normal distribution by the Kolmogorov-Smirnov (KS) normality test with a = 0.05, analyzed by
Student’s t test, and are presented as mean ± SEM; nR 3 for each group. Data in panels (D)–(F) were analyzed by the Mann-Whitney test. See also Figure S1.(E values % 44 by standard BLASTP search) (Altschul et al.,
2005) with the eukaryotic enzyme serine palmitoyltransferase
(SPT). SPT, the first committed enzyme in sphingolipid bio-
synthesis, produces 3-ketosphinganine from palmitoyl-coen-
zyme A and L-serine (Lowther et al., 2012). We knocked out
gene BF2461 from wild-type B. fragilis NCTC 9343 (BFWT) to
create a mutant strain BFDSPT, and we complemented this
mutant with a full copy of BF2461 in trans (C-delta). We found
that the BFWT and BFDSPT in vitro growth kinetics were gener-
ally comparable, although BFDSPT had a slightly longer doubling
time (64 ± 0 min versus 74 ± 1 min; Figure S1A). Using thin-layer
chromatography, we compared lipid extracts from BFWT and
BFDSPT strains and identified several spots that were present
in the former but lacking in the latter. We further treated the
two samples with mild alkaline hydrolysis to differentiate sphin-
golipids from phospholipids, the latter being the most common
components of bacterial lipid membranes. The spots that were
unique to the BFWT strain were indeed sphingolipids, as deter-
mined by their resistance to hydrolysis. In comparison, the spots
that were present in both strains were hydrolyzed after treat-
ment, a result suggesting that these spots were phospholipids.
C-delta conferred thewild-type profile of sphingolipid generation
(Figure S1B).
After monocolonizing GF mice with either BFWT bacteria
(termed BFWT mice) or BFDSPT bacteria (termed BFDSPT
mice), we monitored absolute and relative numbers of iNKT cells
in their pups’ colonic LP from birth to 9weeks of age, aswell as in
age-matched GF and SPF mice (Figures 1A–1C). We found that124 Cell 156, 123–133, January 16, 2014 ª2014 Elsevier Inc.iNKT cells were absent from the colon in all mice at birth but then
were present in numbers that gradually increased until they
reached steady state at the age of 6weeks. However, the relative
(to CD3+ T cells) and absolute numbers of iNKT cells were sig-
nificantly higher in GF and BFDSPT mice than in SPF and
BFWT mice, despite lower cell numbers in BFDSPT mice than
in GF mice. We also found that colonic LP CD3+ T cell numbers
were similar among GF, BFWT, and BFDSPT mice (Figure S1C).
These results suggest that bacterial sphingolipids from a single
microbe, B. fragilis, negatively regulate iNKT cell numbers in
the colon, although we do not know whether colonic iNKT cells
from the BFWT and BFDSPT mice are functionally similar (e.g.,
whether they have the same capacity for cytokine production
upon activation). In addition, C-delta-monoassociated mice
had colonic iNKT cell numbers similar to those observed in
BFWT mice (Figure S1D).
In previous comparisons of iNKT cell numbers in SPF and GF
mice, we found that SPF animals had higher numbers in the
thymus, spleen, and liver but lower counts in the colon and
lung (Olszak et al., 2012). In the current studies, we found that,
despite differences in the numbers of iNKT cells in the colon,
BFWT mice did not differ from BFDSPT or GF mice in terms of
iNKT cell numbers in the lung, liver, small intestine, thymus,
spleen, or Peyer’s patches (Figures 1D–1F and S1E–S1G). These
results indicate thatB. fragilis sphingolipids exert effects on iNKT
cells only in the colon, where this bacterium is most abundant. A
possible reason for the local effect of the B. fragilis glycosphin-
golipids in these mice is that their quantity, stability, and/or
Figure 2. B. fragilis Sphingolipids Modulate the Host Oxazolone-Induced iNKT Cell-Mediated Colitis Phenotype
(A and B) Upon oxazolone colitis challenge, BFDSPTmice hadmore severe weight loss (A; nR 6; p values compare BFWTOxa and BFDSPTOxa at days 3 and 4,
respectively) and higher cumulative histopathology scores (B) compared with BFWT mice.
(C–E) In tissue explant cultures, levels of IL-13 (C) and IL-4 (D) production in colonic tissue after oxazolone challenge were higher in BFDSPT mice than in BFWT
mice, although IL-1b production was not (E).
Data in (A) were confirmed to have normal distribution by the KS normality test with a = 0.05, analyzed by Student’s t test and are presented asmean ± SEM. Data
in (B)–(E) were analyzed by the Mann-Whitney test and are plotted with box plots. Whiskers are minima and maxima of the data; nR 3 for each group; repre-
sentative of three experiments. See also Figure S2.potency are not high enough to have an effect outside the large
intestine for iNKT cell regulation.
To investigate whether the difference in colonic iNKT cells
between BFWT and BFDSPT mice has biological significance,
we subjected these mice to an oxazolone colitis challenge, in
which intestinal inflammation characteristic of human ulcerative
colitis is induced and is dependent on iNKT cell-produced inter-
leukin 13 (IL-13) (Boirivant et al., 1998; Fuss et al., 2004; Heller
et al., 2002). As expected, BFDSPTmice hadmore severeweight
loss (Figure 2A), higher cumulative histopathology scores (Fig-
ure 2B), and higher levels of IL-13 and IL-4 release than BFWT
mice, although the difference in IL-1b production was not sig-
nificant (Figures 2C–2E). Furthermore, we confirmed that the
BFDSPT mouse phenotype was CD1d dependent: blocking of
CD1d with a monoclonal antibody (19G11) during the neonatal
period reduced iNKT cell numbers and prevented the colitis
phenotype when these mice were challenged in adulthood (Fig-
ure S2A–S2C). It is possible that different functional characteris-
tics (e.g., cytokine production during colitis stimulation) of the
iNKT cells from these two monoassociated mice may also
partially contribute to the colitis results. Nonetheless, our results
showed a direct link between symbiotic bacterial sphingolipids
and both host iNKT cell homeostasis and disease susceptibility.
B. fragilis Sphingolipids Inhibit Host Colonic iNKT Cell
Proliferation during Neonatal Development
We next investigated a number of possible causes for our find-
ings that mice monocolonized with BFWT and BFDSPT had
different iNKT cell homeostasis in the colonic LP. We studied
the relative numbers of BFWT and BFDSPT bacteria contained
within the colons, including microbes that were either in the
lumen or tissue associated (Figures S3A and S3B), and we did
not find appreciable differences in bacterial numbers between
the two strains in any condition tested. We next studied the abil-
ity of B. fragilis to normalize the elevated colonic levels of
CXCL16 observed in GF mice (Olszak et al., 2012) and found
that the two types of monocolonized mice had similar cxcl16mRNA levels in the colon tissues, comparable to that of the GF
mice (Figure S3C). Third, we analyzed the activation (Wingender
et al., 2012; Figure S3D) and apoptosis (Table S1) of colonic iNKT
cells in BFWT and BFDSPT mice and found little difference.
Lastly, we investigated whether PSA expression was quantita-
tively different between the BFWT and BFDSPT strains, which
could lead to differential activation of PSA-mediated pathways
(Figure S3E). We found that PSA production levels were statisti-
cally identical in the two strains. Thus, we discovered no evi-
dence to support any of the above mechanisms accounting for
the differences in iNKT cell homeostasis in mice colonized with
BFWT versus BFDSPT bacteria.
One other possibility we considered was that some bacterial
sphingolipids, including those of B. fragilis, inhibit the expansion
of the iNKT cell population in the colon. To test this hypothesis,
we measured the expression of Ki-67 (a nuclear protein marker
for cellular proliferation) in iNKT cells within the colonic LP of
mice from birth to 9 weeks of age. We found significantly higher
mean fluorescence intensity (MFI) expression for this protein in
both GF and BFDSPT mice than in either SPF or BFWT mice
during the neonatal period, particularly between days 5 and 12.
At 8 days of age, the percentage of Ki-67+ iNKT cells was also
higher in GF and BFDSPT mice. Proliferation was reduced to
similar low levels in all mice after 21 days (Figures 3A, S3F,
and S3G). To verify this observation, we used an alternative
approach—the bromodeoxyuridine (BrdU) method—to measure
DNA replication in colonic LP iNKT cells in 8-day-old mice. We
confirmed that GF and BFDSPT mice had higher levels of DNA
replication in these cells than did SPF and BFWT mice, respec-
tively (Figures 3B and S3H). These studies showed that symbi-
otic bacterial sphingolipids can modulate the homeostasis of
colonic iNKT cells by inhibiting cell proliferation, and thus their
accumulation, during neonatal development.
On the basis of these findings, we hypothesized that only when
mice are exposed to symbiotic sphingolipids very early in life are
their iNKT cell numbers restricted in adulthood.Wedesigned two
cohousing experiments to test this hypothesis. In the firstCell 156, 123–133, January 16, 2014 ª2014 Elsevier Inc. 125
Figure 3. B. fragilis Sphingolipids Inhibit Colonic LP iNKT Cell Proliferation during Neonatal Development and Restrict the Accumulation of
These Cells in Adult Mice
(A and B) Proliferation rates (nR 3) were higher in GF and BFDSPT mice than in SPF and BFWT mice at early ages.
(C and D) Colonic LP iNKT cell counts were not restored in GF-WT(adu) mice, but GF-WT(neo) mice had levels of colonic LP iNKT cell proliferation and total cell
numbers similar to those in BFWT mice.
(E and F) After oxazolone challenge, only GF-WT(adu) mice had severe weight loss and high cumulative histopathology scores (nR 10; p value in E compares
BFWT and BF-WT(adu) mice at day 4).
Data in (A) (days 8 and 12) and (E) were confirmed to have normal distribution by the KS normality test with a = 0.05, analyzed by Student’s t test and are presented
asmean ± SEM. Data in (B)–(D) and (F) were analyzed by theMann-Whitney test and are plotted with box plots. Whiskers are minima andmaxima of the data. See
also Figure S3 and Table S1.experiment, GF dams were mated with BFWT monocolonized
mice. Ki-67 expression in offspring pups’ colonic LP iNKT cells
was measured at 8 days of age (Figure 3C) and iNKT cell
numbers were measured at 8 weeks (Figure 3D). As expected,
the proliferation levels and total cell numbers in pups born to
dams receiving BFWT bacteria (GF-WT(neo)) were similar to
those in BFWT mice. In the second experiment, we cohoused
GF pups at 10–14 days of age with BFWT mice (GF-WT(adu)),
just after the cell proliferation window had closed. As expected,
although GF-WT(adu) mice harbored numbers of BFWT bacteria
equivalent to those in GF-WT(neo) mice, the GF-WT(adu)
animals had much higher colonic LP iNKT cell numbers at
8 weeks of age. Whenwe challenged thesemice with oxazolone,
GF-WT(neo) mice responded similarly to BFWT mice, with a
significant reduction in the severity of the colitis phenotype and
intestinal inflammation (as assessed by weight loss and colitis
scores) from values obtained in GF-WT(adu) mice (Figures 3E
and 3F). These studies established a critical time window for
exposure to sphingolipid-producing symbionts to maintain
host iNKT cell homeostasis and influence disease susceptibility.
Interestingly, when we cohoused GF pregnant dams with BFWT
mice 3 days before delivery, the pups’ colonic iNKT cell numbers
were not normalized to the BFWT level but more resembled the
numbers found in GF mice, although at time of delivery, the
mother was heavily colonized with BFWT bacteria (data not126 Cell 156, 123–133, January 16, 2014 ª2014 Elsevier Inc.shown). This finding indicates that either bacterial sphingolipids
are important for iNKT cell development at the prenatal stage or
as yet unidentified factors also control iNKT cell homeostasis.
Purified B. fragilis Glycosphingolipids Inhibit iNKT Cell
Activation In Vitro and In Vivo
In order to identify bioactive sphingolipids of B. fragilis, we per-
formed comparative lipidomic profiling of BFWT and BFDSPT
bacteria by high-performance liquid chromatography tandem
mass spectrometry (HPLC-MS/MS). In BFWT lipid extracts, we
identified three types of sphingolipids with characteristic MS/
MS fragmentation patterns: ceramides (Cers), glycosylcera-
mides (GL-Cers, signature fragments of 161,179), and phos-
phoethanolamine-ceramides (PE-Cers, signature fragment of
140) (Figure 4A; data not shown). None of these sphingolipids
were detected in BFDSPT lipid extracts. To determine whether
any of these sphingolipids activated iNKT cells, we conducted
coculture assays. Bone marrow dendritic cells (BMDCs) were
pulsed with each sphingolipid type and then incubated with
iNKT cell hybridoma 24.7. None of the lipids in the tested condi-
tions activated iNKT cells to produce appreciable IL-2, although
the prototypical ligand KRN7000 caused robust activation (Fig-
ure 4B). We next tested whether these lipids were inhibitory to
iNKT cells. We pulsed BMDCs with each sphingolipid type in
the presence of KRN7000 and then incubated the cells with
Figure 4. Chemical Analysis of B. fragilis Glycosphingolipid Peak GSL-Bf717
(A) Three distinct sphingolipid clusters were identified in B. fragilis.
(B) None of these clusters activated iNKT cells. The data are representative of two experiments (each done in triplicate) and presented as median ± range.
(C) GL-Cers was inhibitory to iNKT cell activation by KRN7000 in vitro. The data were compiled from three experiments (nR 6) andwere confirmed to have normal
distribution by the KS normality test with a = 0.05, analyzed by Student’s t test, and are presented asmean ± SEM. The p values compare KRN7000 +GSL-Bf717
(at ratios of 1:10 and 1:30) with KRN7000 alone (ratio 1:0).
(D) GL-Cers had five chain-length variants (C32–C36), and C34 with MW = 717.6 (m/z 716) was predominant.
(E–G) A peak from this variant, GSL-Bf717, was characterized by MS/MS (E), HPAEC (F), and 1H-NMR (G) and was found to have an a-galactosyl linkage. In (F),
the hydrolyzed hexose head group coeluted with the spiked galactose standard (red) at 12.6 min.
(H) The proposed molecular configuration of GSL-Bf717 is shown for comparison with that of the prototypical agonist KRN7000.hybridoma 24.7, measuring the production of IL-2 as an indicator
of iNKT cell activation (100% activation was defined by the level
of IL-2 production in the KRN7000 alone condition). In this assay,
GL-Cers, but not the other two lipid types, significantly reduced
iNKT cell activation by KRN7000 (Figure 4C). It is very likely
that the difference in activity among the three classes of lipid
molecules lies in the different head groups. It is possible that
the hexose, in combination with certain unique features of
bacterial ceramide chains, allows GL-Cers to interact more
stably with CD1d and/or iNKT cells as compared with PE-Cers
and Cers.
To identify molecules inhibitory to iNKT cell activation, we
further analyzed the GL-Cers cluster. We found that GL-Cers iscomposed of multiple molecular species, ranging from m/z 688
tom/z 744 (Figure 4D). The observation that all species had char-
acteristic fragments at m/z 143, 161, and 179, which were from
the hexose head group, implied that the source of the structural
variability resided in the chain length of ceramide structures from
C32 to C36 (Figure 4E; data not shown). MS/MS analysis of a
prominent m/z 716 peak (C34: MW = 717.6) generated multiple
daughter ions—assigned as m/z 698 ([M-H-H2O]), 680 ([M-H-
2H2O]), 554 ([M-H-hexose+H2O]), 536 ([M-H-hexose]), and 490
([M-H-C15H29O])—in addition to the above-mentioned hexose-
derived fragments. Among these daughter ions, m/z 490 (loss
of the hydroxyl aliphatic chain) assigned that sphingosine and
the fatty acid chain have one hydroxyl group each (Figure 4E).Cell 156, 123–133, January 16, 2014 ª2014 Elsevier Inc. 127
Figure 5. B. fragilis GSL-Bf717 Inhibits iNKT Cell Activation
(A–D) GSL-Bf717 did not activate iNKT cells (A and C; data are representative of two independent experiments, each done in triplicate) but did inhibit iNKT cell
activation by agonist KRN7000 (100 nM) in both hybridomas 24.7 and DN32.D3 (B, left columns, and D, data are representative of two independent experiments,
each done in triplicate; p value compares KRN7000 +GSL-Bf717 at a 1:30 ratio with KRN7000 alone, which is at a ratio of 1:0). GSL-Bf717 also inhibited activation
by agonist b-GlcCer (20 mM; right columns in B; p values compare b-GlcCer + GSL-Bf717 at ratios of 40:1 and 20:1 with b-GlcCer alone, which is at a ratio of 1:0).
(E) The loading efficiency of PBS-44 to empty CD1d tetramer (phycoerythrin-labeled) was decreased significantly in the presence of GSL-Bf717, as evidenced
by the reduced MFI of CD1d tetramer-stained iNKT cells; tetramers: PBS-44: GSL-Bf717=1:1:3; n = 4.
(F and G) GSL-Bf717 reduced serum levels of IFN-g (F) and IL-4 (G) released by KRN7000-stimulated iNKT cells in vivo; 100% production was defined as the level
of cytokines produced in KRN7000-only-treated mice (nR 4). Mice were intraperitoneally injected with 1,000 ng of bacterial lipids and/or 100 ng of KRN7000.
Data in (A)–(D) and (F) are presented asmedian ± range. Data in (E) are plotted with box plots. Whiskers are minima andmaxima of the data. Data in (B) and (D)–(F)
were analyzed by the Mann-Whitney test. Data in (G) were confirmed to have normal distribution by the KS normality test with a = 0.05, analyzed by Student’s
t test, and are presented as mean ± SEM. See also Figure S4.The MW 717.6 peak was purified by HPLC and further analyzed.
By high-pH anion-exchange chromatography (HPAEC), we iden-
tified the structure of the monosaccharide head group as galac-
tose (Figure 4F). In addition, we used 1H-NMR (Figure 4G) and
1H-1H-NMR (correlated spectroscopy; data not shown) to verify
the identity of the hexose and characterize its glycosidic linkage.
NMR analysis revealed a galactose residue linked a-glycosidi-
cally to the sphingoid backbone. This a-galactosylceramide
peak is referred to as GSL-Bf717, and a proposed molecular
configuration is shown in Figure 4H. In addition, we confirmed
that GSL-Bf717 was detectable only in fecal samples from
BFWT mice, but not in samples from BFDSPT mice. The esti-
mated yield of GSL-Bf717 was 1 ng per gram of fecal pellet.
Although it shares key features with the known iNKT cell agonist
KRN7000, GSL-Bf717 has unique structural characteristics,
such as shorter chain lengths and different hydroxyl composi-
tions in both chains. Ceramides produced by B. fragilis are
known to have branched acyl chains in iso- or anteiso-positions128 Cell 156, 123–133, January 16, 2014 ª2014 Elsevier Inc.(Miyagawa et al., 1979), which may present yet another dis-
tinction between GSL-Bf717 and KRN7000. As a result of these
dissimilarities, GSL-Bf717 may possibly compete with KRN7000
for the limited space in CD1d grooves, but may be positioned
differently so that the a-galactosyl head group does not interact
with the iNKT cell receptor in the same way as KRN7000. It is
unclear whether GSL-Bf717 and similar molecules are presented
as antagonistic ligands or simply occupy the CD1d binding
space due to high affinity. In either case, the end consequence
is that these bacterial glycosphingolipids and KRN7000 have
opposing immunological effects: GL-Cers restrains iNKT cell
activation and KRN7000 activates iNKT cells.
To confirm that GSL-Bf717 has inhibitory activity, we per-
formed several coculture assays. In cocultures of BMDCs and
iNKT cell hybridoma 24.7, GSL-Bf717 did not activate iNKT cells
(Figure 5A). Moreover, GSL-Bf717 did not activate noninvariant
NKT cell line 14S6 (data not shown). We next conducted a
CD1d-loading experiment using phycoerythrin-stained CD1d
empty tetramers and the iNKT cell hybridoma 24.7. When the
empty CD1d tetramers are loaded with lipid antigens, they can
bind to the iNKT cell receptor and the complex can be detected
by flow cytometry, as shown in Figures S4A–S4D for tetramers
either preloaded at the NIH facility (Figure S4B) or lab loaded
(Figure S4D) with PBS-57 (a lipid variant of KRN7000 that also
stimulates iNKT cells). Previously empty tetramers added with
either one of the three identified lipid fractions (Figure 4A) or
GSL-Bf717 did not bind to iNKT cells (Figures S4E–S4H). In addi-
tion, GSL-Bf717-added, previously empty CD1d tetramers did
not effectively stain liver lymphocytes, in contrast to the control
tetramers loaded with PBS-57 (Figures S4I–S4K). These CD1d-
loading experiments provide supporting evidence that the puri-
fied bacterial lipids do not activate 24.7 iNKT hybridoma cells
in the tested conditions. The likely mechanisms could be that
the lipids do not sit or do not sit correctly in the CD1d-binding
grooves and/or that the iNKT TCRs do not recognize these
CD1d-lipid complexes.
When in competition with KRN7000 at a ratio of 1:30 in the
coculture assay using BMDCs and 24.7 cells, GSL-Bf717 in
excess moderately (i.e., by 40%) inhibited KRN7000-induced
activation of iNKT cells (Figure 5B, left group of columns). This
limited suppressive activity of GSL-Bf717 suggested that it likely
acts as a competitive inhibitor to agonists in binding to CD1d,
instead of as a true antagonist. However, when we tested
another iNKT cell agonist, b-glucosylceramide (b-GlcCer,
d18:1/24:1(15Z)), we found that GSL-Bf717 was more effective
in inhibiting its function. b-GlcCer is an endogenous agonist
that has much weaker activity than KRN7000 (Brennan et al.,
2011). Indeed, in our assay, to induce comparable IL-2 produc-
tion in the 24.7 hybridoma, it took micromolar concentrations of
b-GlcCer as compared with nanomolar concentrations of
KRN7000 (Figure 5A). Remarkably, GSL-Bf717 not only could
inhibit b-GlcCer function in a dose-dependent fashion but also
could achieve 40% inhibition with as little as 2.5% of the
b-GlcCer concentration (Figure 5B, right group of columns,
40:1).We next used the hybridomaDN32.D3 to test the inhibitory
activity of GSL-Bf717 on KRN7000 function. We found that GSL-
Bf717 was not able to activate this iNKT cell line when BMDC
was used as the CD1d-expressing antigen-presenting cell, but
could inhibit iNKT cell activation by KRN7000 to a similar extent
as in 24.7 (Figures 5C and 5D). As seen with hybridoma 24.7,
Cers could not inhibit DN32.D3 iNKT hybridoma cell activation
by KRN7000. A comparison of Figures 4C and 5B shows that
the GL-Cers fraction was a more potent inhibitor of iNKT cell
activation than was GSL-Bf717. It is highly likely that many
B. fragilis glycosphingolipid species can additively or syner-
gistically inhibit iNKT cells just as GSL-Bf717 does. Nonetheless,
GSL-Bf717 is representative of these glycosphingolipids and
can be used to further explore the inhibitory activity of GL-Cers.
To understand at the molecular level the inhibitory activity of
GSL-Bf717, we performed a CD1d tetramer competitive loading
experiment. We incubated PBS-44 (another variant of KRN7000
that is also agonistic to iNKT cells and can be efficiently loaded to
empty CD1d tetramers) with phycoerythrin-labeled unloaded
CD1d tetramers in the presence and absence of GSL-Bf717 in
a 1:1:3 ratio (tetramers/PBS-44/GSL-Bf717). We then used the
CD1d-lipid complex (in excess) to stain iNKT hybridoma 24.7cells and measured the MFI. We found that, in comparison
with the PBS-44+vehicle control, addition of GSL-Bf717 to
PBS-44 was able to significantly reduce the MFI of the stained
iNKT cells to 57% of that of the vehicle control, reflecting the
decreased staining efficiency of the tetramers, as well as the
poor loading capacity of PBS-44 to CD1d in the presence of
GSL-Bf717 (Figure 5E). This experiment strongly suggested
that the inhibitory function of GSL-Bf717 was likely mediated at
the molecular level during CD1d-lipid interactions in which
GSL-Bf717 could occupy the CD1d grooves and prevent PBS-
44 loading, and/or that the GSL-Bf717-loaded CD1d complex
was not recognized properly by the iNKT cells (leading to a
decreased MFI).
To investigate whether GSL-Bf717 inhibits iNKT cell agonist
function in vivo, we intraperitoneally injected KRN7000 (100 ng)
and GSL-Bf717 (1,000 ng) into mice and measured serum inter-
feron-g (IFN-g) and IL-4 production 4 hr later. When adminis-
tered with GSL-Bf717, the ability of KRN7000 to produce both
cytokines in serum was significantly reduced compared with
that of KRN7000 alone; in contrast, PE-Cers at the same dose
coadministered with KRN7000 did not reduce production of
either cytokine (Figures 5F and 5G). In this experiment, the pro-
duction of these cytokines through KRN7000 stimulation was
mediated by iNKT cells and dependent on CD1d expression:
no IFN-g or IL-4 was detected in CD1d-knockout mice in any
group (data not shown). These results demonstrated that GSL-
Bf717 inhibits agonist-induced iNKT cell activation in vivo.
GSL-Bf717 Treatment of BFDSPTMiceRestoresColonic
iNKT Cell Homeostasis and Protects Mice from Colitis
Endogenous lipids provide important antigens that drive in vivo
activation of iNKT cells (Brennan et al., 2011; Rossjohn et al.,
2012). Our studies with KRN7000 suggested that GSL-Bf717
might inhibit in vivo activation and expansion of iNKT cells by
endogenous lipids during the neonatal period. We therefore
administered GSL-Bf717 (100 ng/dose) five times by gavage to
newborn BFDSPT mice at 2–7 days of age, and then measured
the colonic iNKT cell Ki-67 levels at 8 days and total colonic
iNKT cell numbers at 8 weeks. Compared with vehicle-treated
mice, GSL-Bf717-treated BFDSPT mice had significantly lower
levels of Ki-67 expression at a very young age (Figure 6A), as
well as lower cell numbers in adulthood (Figure 6B). When
challenged with oxazolone, GSL-Bf717-treated mice lost less
weight and had lower cumulative histopathology scores
compared with vehicle-treated mice (Figures 6C and 6D). GSL-
Bf717 is certainly not the only lipid that can mediate the above
phenotypes, and it may not even be the most potent one. Yet,
it provides proof-of-principal evidence that bacterial glycosphin-
golipids can be orally administrated to susceptible hosts at
a young age to perhaps permanently limit colonic iNKT cell
numbers and reduce host colitis susceptibility into adulthood.
DISCUSSION
Although in utero development takes place in a sterile environ-
ment, mammals commence a lifelong relationship with microbes
at birth and may be exposed to microbial products through the
placenta during gestation. Symbionts thus have the opportunityCell 156, 123–133, January 16, 2014 ª2014 Elsevier Inc. 129
Figure 6. GSL-Bf717 Treatment of Neonatal BFDSPT Mice Restores
Colonic iNKT Cell Homeostasis and Protects Mice from Colitis in
Adulthood
(A–D) GSL-Bf717-treated mice had lower Ki-67 expression at 8 days (A; nR 4)
and lower total counts of colonic LP iNKT cells at 8 weeks (B; n R 6). These
mice were protected against the oxazolone challenge, with less weight loss (C;
p values compare the two groups at days 1 and 4) and lower cumulative
histopathology scores (D). Data are representative of two independent
experiments; n = 6 for each group. Data in (A), (B), and (D) were analyzed by the
Mann-Whitney test and are plotted with box plots. Whiskers are minima and
maxima of the data. Data in (C) were confirmed to have normal distribution by
the KS normality test with a = 0.05, analyzed by Student’s t test, and are
presented as mean ± SEM.to affect host physiology fromanearly age,whenmanyhost func-
tions are actively evolving. This work offers mechanistic data
that support the growing body of evidence indicating the impor-
tance of early-life microbial exposure in regulating adult immune
homeostasis and disease susceptibility (Ege et al., 2011; Lo´pez-
Serrano et al., 2010; von Mutius, 2007; Olszak et al., 2012; Stra-
chan, 1989). Our results reveal an unexpectedmechanism for the
attainment of host immune balance: symbionts negatively regu-
late a crucial immune cell type, the iNKT cell, and prevent its
excessive activation during a disease challenge. Thismodulation
is fundamentally based on the ability of symbionts to modify the
host lipid environment by means of bacterial glycosphingolipids.
Indeed, the SPT homolog and potentially the ability to synthesize
sphingolipids are well conserved in intestinal Bacteroides spe-
cies (An et al., 2011; Kato et al., 1995), and the availability of these
sphingolipids in the intestines is likely not an issue. Because of
structural similarities with iNKT cell agonists, these nonactivating
sphingolipids effectively blend into the host lipid antigen pool and
turn the hyperproliferating environment during neonatal develop-
ment into a restricted one.Consequently, iNKT cell activation and
expansion caused by indigenous self and microbial stimuli are
reduced. Importantly, in SPF and BFWT mice, despite lower
numbers of colonic iNKT cells in the presence of these bacterial
lipids, these cells still undergo some proliferation during the
neonatal period (Figures 3A and S3G), suggesting that the host’s
endogenous agonists are still recruited to expand the cell popu-130 Cell 156, 123–133, January 16, 2014 ª2014 Elsevier Inc.lation in thesemice.WielandBrownet al. (2013) recently reported
that some B. fragilis sphingolipids can provide weak agonistic
activity to iNKT cells. Because we have found that B. fragilis pro-
duces a variety of sphingolipid species, it is not surprising that
some of the lipid structures are stimulatory while others (as we
are reporting) are inhibitory. It is very important to note that
we have shown here that the total net effect of these lipids, as
demonstrated by comparing the numbers of iNKT cells in colons
of BFWT and BFDSPT mice, is to inhibit iNKT cells in the colonic
LP. GSL-Bf717 serves as a paradigm for these iNKT cell-restric-
tive lipids.
In our previous study comparing iNKT cells in the lung and
colon of SPF and GF mice (Olszak et al., 2012), we identified
increased CXCL16 chemokine release from these tissues as
being responsible for the heightened iNKT cell accumulation in
these tissues observed in GF mice. In the present study, we
found similarly high levels of colonic cxcl16 mRNA expres-
sion in BFWT, BFDSPT, and GF mice. Therefore, colonization
by the single organism B. fragilis does not downmodulate
CXCL16 expression in colon tissues and does not modify traf-
ficking of these cells to the colon. However, the bacterial sphin-
golipids in BFWT mice can restrict local proliferation of colonic
iNKT cells once the cells arrive. Ultimately, colonic iNKT cells
achieve homeostasis with smaller total numbers in BFWT mice
compared with BFDSPT mice or GF mice, which do not possess
the bacterial sphingolipids-mediated inhibition of proliferation. It
is remarkable that monocolonization by a single sphingolipid-
producing bacterial species, which does not have the CXCL16
modulation capacity, can have impacts on host iNKT cell ho-
meostasis and colitis susceptibility comparable to those attained
by the whole microbiota, which implements the additional che-
mokine pathway. Taken together, our observations of different
CXCL16 expression in SPF versus GF mice, and different iNKT
cell proliferation in BFWT versus BFDSPT mice, suggest that
the microbiome uses multiple, perhaps organism-specific,
mechanisms to keep the number of iNKT cells in check.
The inhibitory bacterial glycosphingolipids further blur the
conventional distinction between self and nonself in terms of
immune recognition. Evidence in this study suggests that the
host is strongly dependent on bacterial glycosphingolipid mole-
cules for iNKT cell homeostasis during development. Strikingly,
our data show that an absence of these decisive molecules in
youngGF and BFDSPTmice has a lasting impact on the animals’
iNKT cell homeostasis and causes an irreversible increase in
their susceptibility to colitis. Our results highlight the importance
of sphingolipid-producing symbionts as a vital component of the
colonic microflora in early life, despite the fact that they are
probably not the dominant members of intestinal community at
this age (Koenig et al., 2011; Yatsunenko et al., 2012). It is also
possible that the inhibitory bacterial sphingolipids are passed
to the pups from dams through milk. Nevertheless, although
the enzymatic pathway required for production of these
glycosphingolipids is not encoded in the eukaryotic genome,
we propose these molecules—exemplified by GSL-Bf717—as
prototypes for self-inhibitors of iNKT cells, which is currently a
scarcely explored yet important field in iNKT cell biology.
Our results also suggest a paradigm for host-symbiont inter-
actions. In host-pathogen interactions, specific virulence factors
directly target host cells and pathways with high efficacy and
result in specific immunologic response profiles. Herein, we
report that, in contrast to pathogens, symbionts rather indirectly
and subtly change the chemical environment mediating host
functions. Instead of active stimulation, which has a palpable
impact on host tissues, symbiosis factors (glycosphingolipids
in this study) act silently, passively, and with relatively lower effi-
ciency (because one molecule can occupy only one CD1d
groove). The overall mode of action by symbiosis factors is to
regulate rather than to stimulate. Ineptitude in stimulating the
host immune system results in their evasion of host immune
surveillance and continual association with the host. The timing
of the symbiotic molecules’ activity depends not on microbes
but on host physiological factors such as neonatal development
and possibly immune stimulation. The lower efficiency of the
symbiotic microbial molecules is compensated for by the bulk
presence of these factors and the huge numbers of microbes
producing them (Ley et al., 2006; Zitomersky et al., 2011). We
propose that these attributes are essential for establishing a
symbiotic relationship between microbes and immune systems.
It is tempting to speculate that other, still unidentified symbiosis
factors may function in a similar way to control host immune
homeostasis. In addition, although both are a-glycosphingoli-
pids, GSL-Bf717 is the diametrical opposite—in terms of
function—of the sphingolipids produced by pathobiont Sphingo-
monas species. This observation likely reflects the fine structural
differences between these molecules that result in dissimilar
interactions with CD1d and the iNKT cell receptor. More impor-
tantly, the opposite phenotypes reflect their profoundly different
relationships with the host and highlight a fundamental distinc-
tion between symbiosis and pathogenesis.
Along with our studies of PSA, our evidence regarding the
function of GSL-Bf717 offers insight into the functions of micro-
biota at themolecular level. PSA andGSL-Bf717 are synthesized
from the same bacterium (B. fragilis) but function differently: PSA
facilitates maturation of a balanced CD4+ T cell population,
regardless of the host’s age, whereas GSL-Bf717 is crucial to
iNKT cells in a specific time window of life. These examples,
although thus far limited, strongly indicate that microbes deeply
modulate host immune functions with diverse effects. In addi-
tion, with their unusual inhibitory properties, GSL-Bf717 or inhib-
itors yet to be discovered in the microbiota may offer promise as
novel therapeutic agents that can target the deleterious impact
of iNKT cells in many human disorders (Braun et al., 2010;
Fuss et al., 2004; Matangkasombut et al., 2009; Peternel and
Kastelan, 2009).EXPERIMENTAL PROCEDURES
Mice and Cells
Swiss Webster mice maintained under SPF or GF conditions were purchased
from Taconic USA. C57BL/6 wild-type mice were purchased from The Jack-
son Laboratory. CD1d-deficient mice (Smiley et al., 1997) were maintained
in a SPF barrier facility at Harvard Medical School. GF and monoassociated
mice were bred and maintained in vinyl isolators in the animal facility at
Harvard Medical School. BMDCs were purified from mouse femurs and
cultured for 8 days in C-RPMI-10 with granulocyte-macrophage colony-stim-
ulating factor (20 ng/ml; Biosource). All procedures were approved by the
Harvard Medical Area Standing Committee on Animals.Bacterial Culture and Mutant Construction
B. fragilis strain NCTC 9343 was grown in flasks in an anaerobic chamber in
rich medium (An et al., 2011). Mutant strain BFDSPT was constructed with a
pNJR6 suicide vector; the first 50 and last 94 nucleotides of gene BF2461
were retained, and the 1,041 intervening nucleotides were deleted (Comstock
et al., 1999). The complemented strain C-delta, maintained by erythromycin at
20 mg/ml, was constructed by expression of the full BF2461 gene on plasmid
PFD340 and conjugation of the complementing plasmid to the BFDSPT
mutant.
Cohousing Experiment
GF females or young (10- to 14-day-old) GF pups and their dams were
cohoused in an isolator with BFWT mice (male for mating with GF females
and female for the litters) for an extended period. Effective colonization by
BFWT bacteria was verified by examination of stool samples from adult
mice after 24 hr.
B. fragilis Lipid Extraction
Total bacterial sphingolipidswere purified from overnight anaerobic cultures of
B. fragilis (either BFWT or BFDSPT) by a modified Bligh-Dyer method. Washed
bacterial pellets were stirred overnight in chloroform/methanol/water (1:2:0.8).
The insoluble fraction was precipitated. The liquid fraction was mixed with
equal volumes of chloroform and water (final composition 1:1:0.9) and centri-
fuged for phase separation. The lower organic phase was then collected,
dried, and resuspended with the initial eluent. An open silica column was
used to fractionate the purified lipids with stepwise increases in the polarity
of the eluents (i.e., chloroform/methanol at ratios of 8:1 to 1:2). Each fraction
was dried and resuspended in chloroform. For differentiation of sphingolipids
from nonsphingolipids, total lipids were treated with 0.02 N NaOH for 30min at
37C before being subjected to thin-layer chromatography. Lipid stocks
(10 mg/ml) were prepared in chloroform, and working solutions (1 mg/ml)
were prepared in DMSO.
Lipidomic Profiling
To identify BFWT-specific sphingolipids, silica column-fractionated lipid
fractions of the BFWT and BFDSPT strains were analyzed by reverse-phase
HPLC-MS/MS (Agilent C18 column connected with Thermo Scientific LTQ-
XL; gradients of water to methanol, 10:90 to 0:100) to identify spots present
in BFWT but missing in BFDSPT. Identified lipid species of interest were puri-
fied by reverse-phase HPLC (Varian Prostar/Agilent C18 column) and sub-
jected to structural analysis.
CD1d Tetramer Loading and Staining Assay
For single lipid loading, phycoerythrin-tagged, unloaded-mCD1d tetramers
(1 mM; NIH Tetramer Core Facility) were incubated overnight with 4 mM
lipids in a 10 ml volume. After three washes with PBS, the complex was
resuspended in 10 ml of water. The solution (5 ml) was used to stain iNKT
cell hybridoma 24.7 or liver lymphocytes (1 3 105 cells), together with fluo-
rescein isothiocyanate-labeled anti-CD3ε (or TCR-b; 1 ml) and 7-AAD (5 ml)
in a total volume of 50 ml for 30 min at 4C. Cells were then analyzed by
flow cytometry. For competitive loading, the 1 mM empty tetramers were
incubated with 4 mM PBS-44 in the presence or absence of 12 mM bacterial
lipid GSL-Bf717 in a total volume of 6 ml PBS-0.1% Tween 20. PBS was used
as the vehicle control. After incubation for 6–8 hr at 37C in the dark, each
incubation mixture was washed and 15% of the mixture was then used to
stain iNKT cell hybridoma 24.7 as described above. PBS-57 and PBS-44
were provided by Dr. Gurdyal Besra (University of Birmingham) and
Dr. Paul Savage (Brigham Young University), respectively.
BMDC/T Cell Coculture Assay
BMDCs (100 ml; 5 3 105 cells/ml) were pulsed with lipids in a 96-well plate in
triplicate for 4 hr at 37C. The wells were washed three times before addition
of NKT hybridoma cells of lines 24.7 (Behar et al., 1999), DN32.D3 (Lantz and
Bendelac, 1994), and 14S6 (Behar et al., 1999) in a 200 ml volume (2.5 3 105
cells/ml). After 24 hr at 37C, culture supernatants were subjected to IL-2
ELISA (R&D). For competition assays, bacterial lipids and KRN7000
(100 nM; Avanti Polar Lipids) or b-GlcCer (20 mM, C24:1 glucosyl(b) ceramideCell 156, 123–133, January 16, 2014 ª2014 Elsevier Inc. 131
[d18:1/24:1(15Z)]; Avanti Polar Lipids) were pulsed simultaneously with
BMDCs.
In Vivo Cytokine Inhibition Assay
C57BL/6 wild-type or CD1d-knockout mice (6 weeks old) received one
100 ml intraperitoneal injection of KRN7000 (1 mg/ml) or vehicle control
(0.9% NaCl). In certain groups, this injection was followed by an intraperito-
neal injection of 100 ml (10 mg/ml) bacterial lipid GSL-Bf717 or PE-Cers (esti-
mated MW z 678). Each wild-type group included four to eight mice, and
each CD1d-knockout group consisted of two mice. After 4 hr, serum samples
were prepared and subjected to ELISA for measurements of IFN-g and IL-4.
Lipid Treatment
GSL-Bf717 was purified and dissolved in ethanol at a concentration of
200 mg/ml. Before treatment, the lipid sample was diluted in 0.9% NaCl to a
concentration of 100 ng/30 ml. A 30 ml volume of the GSL-Bf717 solution or
0.9% NaCl was administered by oral gavage to newborn BFDSPT mice (in
an isolator) five times during the first week of life; polyethylene tubing with
an inside diameter of 0.28 mm and an outside diameter of 0.61 mm (BD)
was used for gavage. For oxazolone colitis challenge studies, 6- to 8-week-
old female mice were used.
For further details regarding the materials and methods used in this work,
see the Extended Experimental Procedures.
Statistical Analysis
A two-tailed, nonpaired Student’s t test or two-tailed Mann-Whitney test was
used to determine p values as specified in each figure legend. One-way
ANOVA was performed for multigroup comparison and reported in Table S2.
Statistical significance was defined as p < 0.05. Detailed reports for each
test are listed in Table S2. Horizontal lines in dot plots representmedian values,
and each dot represents one mouse. Whiskers in box plots are the minima and
maxima of the data.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, four
figures, and two tables and can be found with this article online at http://dx.
doi.org/10.1016/j.cell.2013.11.042.
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